NasdaqCM:RWLK

Stock Analysis Report

Executive Summary

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • ReWalk Robotics has significant price volatility in the past 3 months.
  • ReWalk Robotics is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has ReWalk Robotics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.9%

NasdaqCM:RWLK

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

-86.5%

NasdaqCM:RWLK

8.7%

US Medical Equipment

1.7%

US Market

RWLK underperformed the Medical Equipment industry which returned 8.7% over the past year.

RWLK underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

RWLKIndustryMarket
7 Day-1.9%-1.2%1.2%
30 Day-1.9%1.4%4.9%
90 Day-38.1%4.8%3.7%
1 Year-86.5%-86.5%9.6%8.7%3.9%1.7%
3 Year-97.8%-97.8%70.8%65.5%47.2%37.7%
5 Year-99.5%-99.5%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is ReWalk Robotics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ReWalk Robotics undervalued based on future cash flows and its price relative to the stock market?

1.34x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for ReWalk Robotics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for ReWalk Robotics to establish if it is available at substantial discount.


Price Based on Earnings

ReWalk Robotics is loss making, we can't compare its value to the US Medical Equipment industry average.

ReWalk Robotics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ReWalk Robotics, we can't assess if its growth is good value.


Price Based on Value of Assets

ReWalk Robotics is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is ReWalk Robotics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

22.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ReWalk Robotics's revenue is expected to grow significantly at over 20% yearly.

ReWalk Robotics is not considered high growth as it is expected to be loss making for the next 1-3 years.

ReWalk Robotics's revenue growth is expected to exceed the United States of America market average.

Unable to compare ReWalk Robotics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare ReWalk Robotics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ReWalk Robotics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has ReWalk Robotics performed over the past 5 years?

0.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ReWalk Robotics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare ReWalk Robotics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ReWalk Robotics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ReWalk Robotics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ReWalk Robotics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ReWalk Robotics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ReWalk Robotics's financial position?


Financial Position Analysis

ReWalk Robotics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ReWalk Robotics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ReWalk Robotics's level of debt (45.6%) compared to net worth is high (greater than 40%).

Unable to establish if ReWalk Robotics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ReWalk Robotics has sufficient cash runway for 1.8 years based on current free cash flow.

ReWalk Robotics has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -24.4% each year.


Next Steps

Dividend

What is ReWalk Robotics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ReWalk Robotics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ReWalk Robotics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ReWalk Robotics has not reported any payouts.

Unable to verify if ReWalk Robotics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ReWalk Robotics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ReWalk Robotics's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Larry Jasinski (62yo)

7.6yrs

Tenure

US$769,673

Compensation

Mr. Lawrence J. Jasinski, also known as Larry, BS, MBA has been the Chief Executive Officer at ReWalk Robotics Ltd. (formerly Argo Medical Technologies) since February 2012. From 2005 to 2012, Mr. Jasinski ...


CEO Compensation Analysis

Larry's remuneration is higher than average for companies of similar size in United States of America.

Larry's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.9yrs

Average Tenure

62yo

Average Age

The average tenure for the ReWalk Robotics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

5.7yrs

Average Tenure

60yo

Average Age

The tenure for the ReWalk Robotics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$2,33110 Jun 19
Ofir Koren
EntityIndividual
Shares358
Max PriceUS$6.52
SellUS$9429 Nov 18
Lawrence Jasinski
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares15.68
Max PriceUS$6.00

Ownership Breakdown


Management Team

  • Ami Kraft (76yo)

    Executive Advisor to the CEO

    • Tenure: 1.9yrs
    • Compensation: US$310.00k
  • Larry Jasinski (62yo)

    CEO & Director

    • Tenure: 7.6yrs
    • Compensation: US$769.67k
  • John Hamilton (65yo)

    Consultant

    • Tenure: 2.7yrs
    • Compensation: US$258.00k
  • Miri Pariente (42yo)

    Vice President of QA & Operations

    • Tenure: 2.6yrs
  • Ori Gon (39yo)

    Chief Financial Officer

    • Tenure: 1.6yrs
    • Compensation: US$461.95k
  • Andy Dolan

    Vice President of Marketing & Reimbursement

    • Tenure: 1.5yrs
  • Judy Kula

    Vice President of Customer Service

    • Tenure: 1.5yrs

Board Members

  • Wayne Weisman (63yo)

    Independent Director

    • Tenure: 10.7yrs
    • Compensation: US$25.00k
  • Bill Poduska (81yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: US$69.51k
  • Jeff Dykan (60yo)

    Chairman of the Board

    • Tenure: 10.7yrs
    • Compensation: US$25.00k
  • Larry Jasinski (62yo)

    CEO & Director

    • Tenure: 7.6yrs
    • Compensation: US$769.67k
  • Pete Wehrly (60yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$61.37k
  • Yohanan Engelhardt (61yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$51.56k
  • Arik Dan (60yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$25.00k
  • Yasushi Ichiki (51yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: US$25.00k
  • Allen Han (25yo)

    Director

    • Tenure: 0.3yrs

Company Information

ReWalk Robotics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ReWalk Robotics Ltd.
  • Ticker: RWLK
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$23.179m
  • Shares outstanding: 7.29m
  • Website: https://www.rewalk.com

Number of Employees


Location

  • ReWalk Robotics Ltd.
  • 3 Hatnufa Street
  • 6th Floor
  • Yokne'am Illit
  • 2069203
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RWLKNasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDSep 2014
2RWDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2014

Biography

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:54
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.